跳至主要内容
临床试验/EUCTR2007-003736-34-HU
EUCTR2007-003736-34-HU进行中(未招募)1 期

Effect of low dose continuous treatment with Ciclesonide over one year on the time to first exacerbation in children with mild asthma versus intermittent treatment for exacerbations - POPCICLE

ycomed Canada Inc.0 个研究点目标入组 240 人开始时间: 2007年7月10日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
240

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • · Patients giving assent and parents/guardians informed consent
  • · Outpatients, male or female, age 4 to 11 years inclusive
  • · Symptoms consistent with the diagnosis of asthma for at least 12 months not requiring the use of an ICS (less or equal to 250mg/day FP or equivalent) for more than 8 weeks within the last 12 months (no ICS 30 days prior to B0)
  • · FEV1 at least 80 % of predicted, measured at least 4 hours after the inhalation of short acting b2-agonist (e.g. salbutamol), or at least 24 hours after the inhalation of a LABA (salmeterol or formoterol), anticholinergics or the oral intake of theophylline or leukotriene antagonists
  • · Ability to perform reproducible lung function tests
  • · With the exception of asthma, are in good health
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • · History of life-threatening asthma
  • · Hospitalization for asthma within the past 3 months or > or = 2 hospitalizations within the last year.
  • · Asthma exacerbation, or relevant RTI within the last 30 days requiring anti-asthmatic medication beyond an increase in bronchodilator dose
  • · Initiation of immunotherapy within 6 months of B0, or planned initiation within the study period
  • · Severe atopic dermatitis
  • · Concomitant severe diseases or diseases which are contraindicated for the use of ICS
  • · Relevant lung diseases causing alternating impairment in lung function
  • · Prematurely born children (< 36 weeks of gestation)
  • · Conditions [cardiovascular, neurological, hepatic, renal, respiratory (other than asthma or allergic rhinitis), or others] considered as clinically significant
  • · History of cataracts and/or glaucoma
  • · Suspected hypersensitivity to ICS or short-acting ß agonist
  • · Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation
  • · Use of systemic corticosteriods for > 30 days within the previous year, or within 30 days (injectable depot steriods 6 weeks) of B0 or more than 3 times during the last 6 months
  • · Use of drugs not allowed or washout times of drugs cannot be adhered to
  • · Need for concomitant medications that interfere with the study
  • · Lung disease other than asthma, concomitant severe disease
  • · Pregnancy, intention to become pregnant during the trial or lack of safe contraception in females of child-bearing potential
  • · Patients who are mentally incapacitated
  • · Suspected non-compliance or inability to follow the procedures of the study
  • · Participation in another trial within 30 days of enrolment, or previous enrolment in current study
  • · Patient or parents relocation during the study, preventing adherence to visit schedule
  • · Parents or legal representative are, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent from being obtained

研究者

发起方
ycomed Canada Inc.

相似试验